Ko4og 59
JUN - 1 2004
510(k) Summary
McCue Energist ULTRA™ Pulsed Light System
This 510(k) summary of safety and effectiveness for the McCue Energist ULTRA pulsed
light system by McCue Plc is submitted in accordance with the requirements of the Safe
Medical Device Act (SMDA) of 1990 and follows the Office of Device Evaluation (ODE)
guidance concerning the organisation and content of a 510(k) summary.
McCue Plc
Unit 27 Solent Indust. Estate, Hedge End, Southampton. SO23-2FY. England
Steven Peach (General and Technical Manager;
44 1489 795668 __
19" February 2004 _ .

Device Trade McCue Energist ULTRA™

Name: _

Common Name: | Intense Pulsed Light System —

Classification Laser surgical instrument for use in General and Plastic surgery and Dermatology

Name 21 CFR 878.4810
Product Code: GEX

. Panel: 79 oe

Legally-Marketed | The McCue Energist ULTRA™ is substantially equivalent to the following

Predicate currently marketed devices:

Devices: Lumenis, Inc. IPL Quantum, K020839
Radiancy, Inc. SpaTouch, K020856
Radiancy, Inc. Skin Station, KO30897
Palomar, inc. EsteLux, K020453, K020941
Alderm/MBC, Prolite/Plasmalite, KO13365, KO22568, KO23081__ .

System The McCue Energist ULTRA™ is a light-based medical device that delivers a

Description: beam of pulsed non-ionising radiation in the region of 530nm to 950nm. The
system has been designed to be compact and self-contained that includes:

¢ Control console unit

e Display panel

e Power supply

e Cooling system

« Removable handpiece with integrated switch, lamp, filter and glass
_ coupling block . _

Intended Use: The McCue Energist ULTRA™ VPL intense Pulsed Light System is intended for
permanent hair reduction. It is also indicated for photocoagulation of
dermatological vascular lesions, photothermolysis of blood vessels and the
treatment of benign pigmented lesions.

« Intense Pulsed light Energy / wavelengths (530 —- 950nm)
The 530-950nm intense pulsed wavelengths are indicated for :
The treatment of benign pigmented epidermal and cutaneous lesions
including warts, scars and striae.
The treatment of benign cutaneous vascular lesions including port wine
stains, hemangiomas, facial, truncal and leg telangiectasias, rosacea,
melasma, angiomas and spider angiomas, poikiloderma of Civatte, leg
veins, facial veins and venous malformations.
1201
510K summary for ultra 7.doc 25/05/2004 issue 7 page 1 of 2

e Intense Pulsed light Energy / wavelengths (610 — 950nm)
The 610-950nm intense pulsed wavelengths are indicated for :
The removal of unwanted hair from ail skin types, and to effect stable
long-term or permanent’! hair reduction in skin types | - V through
selective targeting of melanin in hair follicles.
” Permanent hair reduction is defined as a long-term stable reduction in the
number of hairs regrowing after a treatment regimen.
Performance The differences in specifications of the McCue Energist ULTRA™ and the
Data: predicate devices do not result in different performance or raise new questions of
safety and efficacy. __
Conclusion: Based on the foregoing, the McCue Energist ULTRA™ system is substantially
equivalent to the legally-marketed predicate devices.
1202
510K summary for ultra 7.doc 25/05/2004 issue 7 page 2 of 2

ain
f & DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
an ee
: Food and Drug Administration
9200 Corporate Boulevard
JUN . 1 2004 Rockville MD 20850
McCue PLC
c/o Mr. John W. Howlett :
British Standards Institution /
Maylands Avenue
Hemel Hempstead
Herts HP2 4SQ
. United Kingdom
Re: K040659
Trade/Device Name: McCue Energist ULTRA™ VPL Intense Pulsed Light System
Regulation Number: 21 CFR 878.4810
Regulation Name: Laser surgical instrument for use in general and
plastic surgery and in dermatology
Regulatory Class: II
Product Code: GEX
Dated: May 12, 2004
Received: May 20, 2004
Dear Mr. Howlett:
We have reviewed your Section 510(k) premarket notification of intent to market the device
referenced above and have determined the device is substantially equivalent (for the indications
for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the Federal Food, Drug,
and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).
You may, therefore, market the device, subject to the general controls provisions of the Act. The
general controls provisions of the Act include requirements for annual registration, listing of
devices, good manufacturing practice, labeling, and prohibitions against misbranding and
adulteration.
If your device is classified (see above) into either class II (Special! Controls) or class II] (PMA), it
may be subject to such additional controls. Existing major regulations affecting your device can
be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may
publish further announcements concerning your device in the Federal Register.
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean
that FDA has made a determination that your device complies with other requirements of the Act
or any Federal statutes and regulations administered by other Federal agencies. You must
comply with all the Act’s requirements, including, but not limited to: registration and listing (21
CER Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic
product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 - Mr. John W. Howlett
This letter will allow you to begin marketing your device as described in your Section 510(k)
premarket notification. The FDA finding of substantial equivalence of your device to a legally
marketed predicate device results in a classification for your device and thus, permits your device
to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please
contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled,
"Misbranding by reference to premarket notification" (21CEFR Part 807.97). You may obtain
other general information on your responsibilities under the Act from the Division of Small
Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or
(301) 443-6597 or at its Internet address http://www. fda.gov/cdrh/dsma/dsmamain.htm!

Sincerely yours,

Mua 6. Prevost
b04 si M. Witten, Ph.D., M.D.
Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and Radiological Health
Enclosure

Indications for Use
510(k) Number (if known):__K040659. :
Device Name:___McCue Energist ULTRA™ VPL Intense Pulsed Light System :
Indications for Use: .
The McCue Energist ULTRA™ VPL Intense Pulsed Light System is intended for permanent hair reduction. It is
also indicated for photocoagulation of dermatological vascular lesions, photothermolysis of blood vessels and the
treatment of benign pigmented lesions.
* Intense Pulsed light Energy / wavelengths (530 — 950nm)
The 530-950nm intense pulsed wavelengths are indicated for : ;
The treatment of benign pigmented epidermal and cutaneous lesions including warts, scars and striae.
The treatment of benign cutaneous vascular lesions including port wine stains, hemangiomas, facial, truncal
and leg telangiectasias, rosacea, melasma, angiomas and spider angiomas, poikiloderma of Civatte, leg
veins, facial veins and venous malformations.
¢ Intense Pulsed light Energy / wavelengths (610 — 950nm)
The 610-950nm intense puised wavelengths are indicated for :
The removal of unwanted hair from al! skin types, and to effect stable long-term or permanent’! hair
reduction in skin types I - V through selective targeting of melanin in hair follicles.
“! Permanent hair reduction is defined as a long-term stable reduction in the number of hairs regrowing after a
treatment regimen.
Prescription Use_X_. OR Over-The-Counter Use
: (Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C) .
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
nr
Concurrence of CDRH, Office of Device Evaluation (ODE)
Page I of |
ee . '
(Division Sign-Off)
ese ‘
Division of General, Restorative,
and Neurological Devices .
D2
: F
510(k) Number_\ 2 F065"

